Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-04
2005-10-04
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S133000, C546S115000, C514S302000
Reexamination Certificate
active
06951868
ABSTRACT:
The invention provides compounds of Formula I:wherein Azabicyclo is any of:These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which α7 is known to be involved.
REFERENCES:
patent: 4605652 (1986-08-01), Welstead
patent: 4612319 (1986-09-01), King
patent: 4797406 (1989-01-01), Richardson et al.
patent: 4798829 (1989-01-01), King et al.
patent: 4835162 (1989-05-01), Abood
patent: 4863921 (1989-09-01), Youssefyeh et al.
patent: 4910193 (1990-03-01), Buchheit
patent: 4920219 (1990-04-01), Pelletier et al.
patent: 4920227 (1990-04-01), Pelletier et al.
patent: 4921982 (1990-05-01), Cohen et al.
patent: 4924010 (1990-05-01), Youssefyeh et al.
patent: 4933445 (1990-06-01), Pelletier et al.
patent: 4935511 (1990-06-01), Youssefyeh et al.
patent: 4983600 (1991-01-01), Ward et al.
patent: 5039680 (1991-08-01), Imperato et al.
patent: 5063231 (1991-11-01), Sanger et al.
patent: 5114947 (1992-05-01), Imondi
patent: 5122528 (1992-06-01), Amondi
patent: 5175173 (1992-12-01), Sun
patent: 5183822 (1993-02-01), Wijngaarden et al.
patent: 5185333 (1993-02-01), Kawakita
patent: 5246942 (1993-09-01), Youssefyeh et al.
patent: 5272154 (1993-12-01), Dixon et al.
patent: 5342845 (1994-08-01), Chokal et al.
patent: 5362734 (1994-11-01), Ward et al.
patent: 5362740 (1994-11-01), Bedeshi et al.
patent: 5434161 (1995-07-01), Becker et al.
patent: 5556851 (1996-09-01), Maryuama et al.
patent: 5561149 (1996-10-01), Azria et al.
patent: 5576434 (1996-11-01), Robinson et al.
patent: 5830902 (1998-11-01), Isaka et al.
patent: 5977144 (1999-11-01), Meyer et al.
patent: 6441049 (2002-08-01), Reitz et al.
patent: 2002/0016334 (2002-02-01), Wadsworth et al.
patent: 0030254 (1980-08-01), None
patent: 0322016 (1988-12-01), None
patent: 0457243 (1991-05-01), None
patent: 483836 (1991-10-01), None
patent: 048596 (1991-11-01), None
patent: 049606 (1991-12-01), None
patent: 0635508 (1992-04-01), None
patent: WO91/09593 (1990-12-01), None
patent: WO91/17167 (1991-04-01), None
patent: WO92/10494 (1991-12-01), None
patent: WO93/06108 (1992-09-01), None
patent: WO9309116 (1993-05-01), None
patent: WO96/33186 (1996-04-01), None
patent: WO97/35860 (1997-03-01), None
patent: WO97/30998 (1997-08-01), None
patent: WO99/20633 (1998-10-01), None
patent: WO00/73431 (2000-05-01), None
patent: WO01/29034 (2000-10-01), None
patent: WO01/36417 (2000-11-01), None
patent: WO01/60821 (2001-02-01), None
patent: WO01/76576 (2001-03-01), None
W.R. Kem,The brain a7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies withDMXBA(GTS-21), Behavioural Brain Research 113(2000) pp. 169-181.
J.E.Macor, et al,The 5-HT Antagonist Tropiestron(ICS 205-930)is a Potent and Selective a7 Nicotinic Receptor Partial Agonist, Biorganic & Medicinal Chemistry Letters 11 (2001), pp 319-321.
A. Orjales, et. al.,Benzimidazole-2-carboxylic acid amides and esters: a new structural class of 5-HT3 ligand, Eur. J. Med. Chem. 34(1999) pp. 415-422.
Acker Brad A.
Groppi, Jr. Vincent E.
Jacobsen Eric Jon
Piotrowski David W.
Walker Daniel Patrick
Aulakh Charanjit S.
Ebel Eileen M.
Ling Lorraine B.
Pfizer Inc.
Richardson Peter C.
LandOfFree
Azabicyclic-phenyl-fused-heterocyclic compounds for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azabicyclic-phenyl-fused-heterocyclic compounds for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azabicyclic-phenyl-fused-heterocyclic compounds for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3449159